ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
-4.37%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$520M
AUM Growth
+$520M
(+7.1%)
Cap. Flow
+$56.8M
Cap. Flow
% of AUM
10.93%
Top 10 Holdings %
Top 10 Hldgs %
45.71%
Holding
253
New
46
Increased
68
Reduced
40
Closed
49
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$14.9M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$9.17M |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
$8.55M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
| 5 |
RAPT Therapeutics
RAPT
|
$5.85M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$11.7M |
| 2 |
Ascendis Pharma
ASND
|
$10.9M |
| 3 |
Mineralys Therapeutics
MLYS
|
$9.18M |
| 4 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
$6.59M |
| 5 |
Sanofi
SNY
|
$4.8M |
Sector Composition
| 1 | Healthcare | 80.96% |
| 2 | Financials | 3.59% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Utilities | 0.02% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
OACCU
26
Oaktree Acquisition Corp. III Life Sciences Unit
OACCU
| $5.39M | 1% |
516,482
+16,482
| +3% | +$172K |
|
|
BBOT
27
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$778M
| $5.31M | 0.99% |
469,729
+65,591
| +16% | +$741K |
|
28
Amylyx Pharmaceuticals
AMLX
$865M
| $5.21M | 0.97% |
+1,471,587
| New | +$5.21M |
|
29
Scholar Rock
SRRK
$3.3B
| $5.05M | 0.94% |
157,079
+137,574
| +705% | +$4.42M |
|
30
Xenon Pharmaceuticals
XENE
$3B
| $4.28M | 0.79% |
127,548
+77,001
| +152% | +$2.58M |
|
31
Xencor
XNCR
$586M
| $4.24M | 0.79% |
398,152
+163,545
| +70% | +$1.74M |
|
|
32
Mineralys Therapeutics
MLYS
$1.93B
| $4.18M | 0.78% |
263,425
-578,116
| -69% | -$9.18M |
|
|
SEPN
33
Septerna, Inc. Common Stock
SEPN
$618M
| $4.17M | 0.77% |
+720,848
| New | +$4.17M |
|
34
Janux Therapeutics
JANX
$1.38B
| $4.15M | 0.77% |
153,767
+122,258
| +388% | +$3.3M |
|
35
Apogee Therapeutics
APGE
$2.26B
| $3.92M | 0.73% |
104,853
+63,579
| +154% | +$2.38M |
|
36
Savara
SVRA
$588M
| $3.77M | 0.7% |
1,360,291
+371,823
| +38% | +$1.03M |
|
37
Monopar Therapeutics
MNPR
$225M
| $3.67M | 0.68% |
100,774
-29,263
| -23% | -$1.07M |
|
|
JBIO
38
Jade Biosciences, Inc. Common Stock
JBIO
$250M
| $3.67M | 0.68% |
1,461,234
+533,218
| +57% | +$1.34M |
|
|
BIOA
39
BioAge Labs, Inc. Common Stock
BIOA
$168M
| $3.65M | 0.68% |
971,100
+848,063
| +689% | +$3.19M |
|
40
Zura Bio
ZURA
$130M
| $3.61M | 0.67% |
2,801,184
+723,933
| +35% | +$934K |
|
41
Astria Therapeutics
ATXS
$383M
| $3.43M | 0.64% |
641,690
+550,706
| +605% | +$2.94M |
|
42
Rezolute
RZLT
$624M
| $3.24M | 0.6% |
1,116,047
-243,161
| -18% | -$705K |
|
|
CNTA
43
Centessa Pharmaceuticals
CNTA
$2.04B
| $3.11M | 0.58% |
216,166
+62,139
| +40% | +$894K |
|
44
Akero Therapeutics
AKRO
$3.6B
| $2.88M | 0.53% |
71,143
+55,836
| +365% | +$2.26M |
|
45
Merus
MRUS
$5.03B
| $2.82M | 0.52% |
66,960
-14,500
| -18% | -$610K |
|
46
PTC Therapeutics
PTCT
$4.36B
| $2.55M | 0.47% |
50,023
+2,000
| +4% | +$102K |
|
47
Regenxbio
RGNX
$474M
| $2.51M | 0.47% |
350,352
+180,223
| +106% | +$1.29M |
|
48
Ardelyx
ARDX
$1.55B
| $2.41M | 0.45% |
490,743
+459,708
| +1,481% | +$2.26M |
|
49
Dynavax Technologies
DVAX
$1.17B
| $2.2M | 0.41% |
+170,000
| New | +$2.2M |
|
50
Arvinas
ARVN
$579M
| $2.2M | 0.41% |
+313,354
| New | +$2.2M |
|